Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Current Deferred Revenue (2019 - 2022)

Lyell Immunopharma (LYEL) has disclosed Current Deferred Revenue for 4 consecutive years, with $11.2 million as the latest value for Q3 2022.

  • Quarterly Current Deferred Revenue rose 100.52% to $11.2 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $11.2 million through Sep 2022, up 100.52% year-over-year, with the annual reading at $5.0 million for FY2021, 88.92% down from the prior year.
  • Current Deferred Revenue hit $11.2 million in Q3 2022 for Lyell Immunopharma, down from $15.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $45.0 million in Q4 2019 to a low of $5.0 million in Q4 2021.
  • Historically, Current Deferred Revenue has averaged $17.7 million across 4 years, with a median of $9.7 million in 2021.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 88.92% in 2021 and later surged 100.52% in 2022.
  • Year by year, Current Deferred Revenue stood at $45.0 million in 2019, then changed by 0.0% to $45.0 million in 2020, then tumbled by 88.92% to $5.0 million in 2021, then surged by 124.36% to $11.2 million in 2022.
  • Business Quant data shows Current Deferred Revenue for LYEL at $11.2 million in Q3 2022, $15.4 million in Q2 2022, and $6.2 million in Q1 2022.